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Abstract 
Aims: This study investigated the chronic effects of twice daily administration of stable 
apelin analogues, apelin-13 amide and (pGlu)apelin-13 amide, on metabolic parameters in 
glucose intolerant and insulin resistant diet-induced obese (DIO) mice fed a high-fat diet for 
150 days. Study Design & Methods: Groups of mice received twice daily (09:00 and 17:00 
h) injections of saline vehicle, apelin-13 amide, (pGlu)apelin-13 amide or exendin-4(1-39) 
for 28 days (all at 25 nmol/kg). Energy intake, body weight, non-fasting blood glucose, 
plasma insulin, glucose tolerance, metabolic response to feeding and insulin sensitivity 
together with pancreatic hormone content and biochemical parameters such as lipids and total 
GLP-1 were monitored. Dual-energy X-ray absorptiometry (DXA) analysis and indirect 
calorimetry were also performed. Results: Administration of apelin-13 amide, (pGlu)apelin-
13 amide or exendin-4 significantly decreased bodyweight, food intake, blood glucose and 
increased plasma insulin compared with high-fat fed saline treated controls (P<0.05 and 
P<0.001), Additionally, all peptide treated groups exhibited improved glucose tolerance (oral 
and ip), metabolic responses to feeding and associated insulin secretion. (pGlu)apelin-13 
amide also significantly improved HbA1c and insulin sensitivity after 28 days.  Both 
(pGlu)apelin-13 amide and exendin-4 increased bone mineral content and decreased 
respiratory exchange ratio (RER), whereas only (pGlu)apelin-13 amide increased energy 
expenditure. All treatment groups displayed reduced circulating triglycerides and increased 
GLP-1 concentrations, although only (pGlu)apelin-13 amide significantly reduced LDL-
cholesterol, total body fat, and increased pancreatic insulin content. Conclusion: These data 
indicate the therapeutic potential of stable apelin-13 analogues with effects equivalent to or 
better than exendin-4.  
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1. INTRODUCTION 
Metabolic syndrome presents an ever-increasing health challenge worldwide, thriving mainly 
because of surplus energy intake and lack of physical activity. 1 It is associated with visceral 
adiposity, impaired insulin sensitivity, hyperglycaemia, dyslipidaemia and hypertension. 2 
Metabolic syndrome is associated with a 5-fold increase in risk for type-2 diabetes and 2-fold 
risk for cardiovascular disease. 3 The prevalence of T2DM is rapidly increasing, especially in 
developing countries, in conjunction with adoption of a westernised lifestyle and increasing 
obesity rates. 4 In addition to correction of lifestyle, diet modifications, increased exercise, 
abstinence from smoking and moderate consumption of alcohol, 5,6 there is an unmet need for 
novel pharmaceutical agents to better help counter diabetes progression and complications.  
 
Glycaemic management in type 2 diabetes requires a complex strategy and patient 
stratification, as a widening array of pharmacological agents are now available.7,8  These 
include, metformin, sulphonylureas, thiazolidinediones, DPP-4 inhibitors, GLP-1 mimetics, 
SGLT-2 inhibitors and, if all else fails to achieve acceptable blood glucose control, therapy 
with insulin. 9 Approximately 80% of individuals with T2DM are overweight or obese, 10 and 
intensive lifestyle intervention could improve fitness, glycaemic control and cardiovascular 
risk factors for relatively small changes in body weight. 11 However due to ineffective energy 
balance, type 2 diabetic subjects who are obese are more likely to require combination drug 
therapy. 12 Thiazolidinediones (TZDs) are more effective in patients with a high BMI, but 
further weight gain, as with insulin, makes them a much less attractive option. 13 GLP-1 
receptor agonists offer a distinct advantage of weight reduction, but nausea is a drawback and 
occasional cases of acute pancreatitis have been reported. 14-15 
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In order to bring forward new and more effective approaches to diabetes therapy, we have 
explored the potential of apelin-13 analogues to lower blood glucose and decrease body 
weight. 16 Apelin is an adipokine, secreted from adipocytes which act on APJ receptors that 
are widely distributed in various tissues including the heart, lung, liver, brain, adipose tissue, 
gastrointestinal tract and bone. 17 Apelin conveys multiple biological actions, including 
regulation of feeding behaviour, glucose utilisation, insulin secretion and blood pressure. 18  
 
To harness the potential of apelin and APJ receptors as target for diabetes, we have developed 
a series of stable analogues of apelin-13, which stimulate insulin secretion and cellular 
glucose uptake in vitro. 16 In acute in vivo studies in mice, these analogues also improved 
glucose tolerance and inhibited feeding, exhibiting protracted effects. 16  In the present study, 
we have examined the effects of chronic twice daily administration of two of the most 
promising analogues, apelin-13 amide and (pGlu)apelin-13 amide, in comparison to the 
established incretin mimetic exendin-4(1-39), on metabolic control in a high-fat fed diet 
induced obese (DIO) mouse model of obesity-diabetes. 
 
2. METHODS 
2.1 Animals 
Male NIH Swiss mice (Harlan Ltd, Blackthorne, UK) were housed individually in an air-
conditioned room (22 ± 2°C) with relative humidity of 51 ± 5% and a 12 h light: dark cycle 
(08:00 – 20:00 h). Animals were maintained on high-fat diet (45% fat, 20% protein, 35% 
carbohydrate; percent of total energy 26.15 kJ/g; Dietex International Ltd., Witham, UK) for 
150 days to produce a model of diet induced obesity (DIO) diabetes.  Normal lean mice 
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received a standard rodent diet (10% fat, 30% protein, 60% carbohydrate; percent of total 
energy 12.99 kJ/g, Trouw Nutrition, Cheshire, UK).  DIO mice exhibited increased body 
weight and elevated non-fasting blood glucose compared with mice receiving a standard 
rodent chow. Drinking water was provided ad libitum and all animal experiments were 
carried out in accordance with the UK Animals (Scientific Procedures) Act 1986 and EU 
Directive 2010/63EU for animal experiments and approved by University of Ulster Animal 
Welfare and Ethical Review Committee. No adverse reactions were observed during the 
treatment period.  
 
2.2  Peptide administration 
Apelin-13 amide, (pGlu)apelin-13 amide and exendin-4(1-39) were purchased from 
(EZBiolabs, Carmel, IN, USA) with a purity of >95%.  Purity and structures were confirmed 
using RP-HPLC and in-house matrix-assisted laser desorption ionization time-of-flight mass 
spectrometry (MALDI-ToF MS), as previously described. 19   To improve the stability, native 
apelin-13 was either amidated at the C-terminus or a pyroglutamate was added at the N-
terminus as previously described. 20 Animals received twice daily intraperitoneal (i.p.) 
injections (0900 and 1700 h) of either 0.9% saline vehicle (lean and high fat-fed control 
group) or of apelin-13 amide, (pGlu)apelin-13 amide or exendin-4(1-39) (each at 25 nmol/kg 
bw) over a 28-day treatment period. This dose was chosen on the basis of previous 
experience with peptides. 16,21  
 
2.3 Measurement of metabolic effects 
Food intake, body weight, non-fasting blood glucose and plasma insulin were measured at 
intervals of 2-3 days throughout the run-in and the 28-day treatment periods. Blood samples 
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were collected from the cut tail vein of conscious mice. Blood glucose was measured using 
an Acensia Contour meter (Bayer Healthcare, Newbury, UK).  For insulin, blood was 
collected in heparin/fluoride microvette (Sarstedt, Numbrecht, Germany), centrifuged (13000 
x g, 3 min) and plasma stored at -20°C prior to measurement by modified dextran coated 
charcoal radioimmunoassay. 22  
 
2.4 Glucose tolerance and insulin sensitivity  
Following the 28-day treatment period, glucose tolerance (18 mmol/kg bw; i.p. and oral) and 
metabolic response to feeding, were examined in overnight (12 h) fasted lean and DIO mice 
treated with either peptides or saline as described previously. 23 Whole body insulin 
sensitivity tests (25 U/kg bw) were carried as described previously using fed mice. 21  
 
2.5 Energy intake and body composition 
Comprehensive Laboratory Animal Monitoring System (CLAMS) metabolic chambers 
(Columbus Instrument, Columbus, OH, USA) were used to measure indirect calorimetry and 
energy expenditure in the peptide treated and lean control groups after 28 days of treatment 
as described previously. 21,24  Respiratory Exchange Ratio (RER) was calculated by dividing 
VCO2 by VO2.  Energy expenditure (EE) was calculated using the equation 
EE = 3.815 + 1.232 × RER) × VO2.  Body composition, bone mineral content and total fat 
mass were measured by DXA scanning (Piximus Densitometer, Fitchburg, WI, USA).  
2.6 Pharmacokinetic study with radiolabelled pGlu(Tyr13)apelin-13 amide 
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The pGlu(Tyr)apelin-13 amide analogue was labeled with 125I according to iodogen method, 
as described previously. 25  Briefly, 35 µl of H2O, 5 µl of 2 M AcOH, 10 µl 1 mM peptide 
(pGlu(Tyr13)apelin-13) and 5 µl of Na-125I (100 mCi/ml stock) was added to iodogen coated 
tubes (5 µg), and vortexed. The reaction mixture was incubated on ice for 30 min with gentle 
agitation once every min. The reaction was terminated by transferring to a new polypropylene 
Eppendorf tube (1.5 ml) washed with 500 µl of sodium phosphate buffer (50 mM) and 
purified using reverse-phase HPLC. The eluent was collected in 1 ml fractions, radioactive 
counts (CPM) analyzed using a 1470 Multigamma counter (Perkin Elmer Wallac Wizard 
1470, San Diego, CA, USA) and highest radioactivity peak was selected for in vivo 
experiments.  The 125I-labelled apelin analogue was administered to mice by i.p. injection at 
4.1 nmol/kg (5 µCi) and blood was collected at various time intervals (from 0-24 h) into 
chilled fluoride/heparin microcentrifuge tubes (Starstedt, Numbrecht, Germany) and 
centrifuged immediately for 2 min at 12,000 g at 4ºC. The resulting plasma was aliquoted in 
fresh low-protein binding Eppendorf tubes and stored at -20ºC.  Correction for free iodine, a 
product of intracellular dehalogenation, was performed by determining radioactivity of pellet 
after precipitation with 10% final concentration of trichloroacetic acid (TCA). The half-life of 
the peptide was calculated from the equation ln(2)/ʎZ.  
 
2.7 Biochemical analyses 
Glycated haemoglobin (HbA1c) was measured using point of care A1CNow+ kit (PTS 
Diagnostic, IN, USA).  Lipid profile including analysis of total cholesterol, triglycerides, high 
density lipoprotein (HDL-C) and low-density lipoprotein (LDL-C) concentrations by I-Lab 
650 clinical analyser (Instrumentation Laboratory, Warrington, UK) as described 
previously.26 Serum amylase (Amylase assay kit, Abcam, UK) and total GLP-1 (ELISA, 
Millipore, UK) were measured from terminal plasma as per manufacturer’s protocols. 
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Pancreatic tissue was excised at the end of the study, weighed and processed for 
measurement of insulin content following extraction with ice-cold acid ethanol. 21,27 
2.8 Statistical analysis 
All results were analysed using GraphPad Prism version 5.0 (GraphPad Software Inc., San 
Diego, CA, USA) and expressed as mean ± S.E.M.  Data were compared using the Student’s 
t-test, one-way and two-way Analysis of Variance (ANOVA) followed by Student–Newman–
Keuls post-hoc test wherever applicable. Area under the curve (AUC) was calculated using 
the trapezoidal rule with baseline correction. Groups of data were considered to be 
statistically significant if p<0.05.  
 
3. RESULTS 
3.1 Effects of apelin-13 amide and (pGlu)apelin-13 amide on metabolic status in DIO 
mice 
Twice daily administration of apelin-13 related peptide analogues resulted in decreased 
bodyweight (p<0.05) which was more marked than observed with exendin-4(1-39) (Fig. 1A). 
A greater % bodyweight change was noted with apelin analogue treatment (p<0.05 to 
p<0.001; Fig 1B).  Mice treated with (pGlu)apelin-13 amide displayed significantly 
decreased cumulative energy intake (p<0.05; Fig. 1C) and a sustained decrease in non-fasted 
blood glucose (p<0.05 to p<0.01; Fig. 1D) which was mirrored by increased non-fasting 
insulin (p<0.05 and p<0.01; Fig. 1E) by day 9. Apelin-13 amide and exendin-4 had no 
significant effects on energy intake, or non-fasting plasma insulin concentrations (Fig. 1C,E) 
but exendin-4 had an antihyperglycaemic effect similar to (pGlu)apelin-13 amide (Fig. 1D).  
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3.2 Effects of apelin-13 amide and (pGlu)apelin-13 amide on glucose tolerance and 
insulin sensitivity in DIO mice 
Treatment with apelin-13 amide, (pGlu)apelin-13 amide or exendin-4(1-39) for 28 days 
significantly decreased blood glucose excursion at 15, 30, 60 and 105 min post i.p. or oral 
glucose tolerance test (p<0.05 to p<0.001; Fig. 2A and Fig. 2E). This was accompanied by 
potentiated glucose-induced insulin secretion (p<0.05 to p<0.01; Fig. 2C and Fig. 2G). 
Integrated responses (area under curve, AUC) to i.p. and oral glucose challenge, showed 
parallel increase in plasma insulin (p<0.01 to p<0.001; Fig. 2D and Fig. 2H) and was 
associated with equivalent blood glucose reductions (p<0.01 to p<0.001; Fig. 2B and Fig. 2F) 
compared to DIO saline treated mice.  
In overnight fasted mice, chronic administration of (pGlu)apelin-13 amide or exendin-4 for 
28 days resulted in significant reductions in blood glucose excursion (p<0.05; Fig. 3A) 
following 15 min feeding compared to high-fat-fed saline treated mice. However, only 
apelin-13 amide and (pGlu)apelin-13 amide exerted a significant stimulatory effect on plasma 
insulin concentrations (p<0.05; Fig. 3B). Additionally, glucose-lowering effects of exogenous 
insulin were enhanced in all groups but were statistically significant in only (pGlu)apelin-13 
amide (p<0.05; Fig. 3C) treated mice. 
 
3.3 Effects of apelin-13 amide and (pGlu)apelin-13 amide on glycated haemoglobin and 
lipid biochemistry, GLP-1, amylase and pancreatic insulin content 
Saline-treated DIO mice showed significantly higher levels of glycated haemoglobin 
compared to lean mice (p<0.01; Fig 4A).  (pGlu)apelin-13 amide administration significantly 
reduced glycated haemoglobin levels compared with saline-treated DIO control mice 
(p<0.05; Fig. 4A).  Elevated concentrations of circulating plasma total cholesterol, exhibited 
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by DIO mice (p<0.01; Fig. 4B) was normalised by administration of exendin-4 (p<0.05), but 
not significantly by apelin analogues (Fig. 4B).  All peptide treatment significantly reduced 
circulating triglycerides (p<0.05 to p<0.01; Fig. 4C). No treatment-related changes in HDL 
cholesterol response were observed in DIO mice (Fig. 4D). However, treatment with 
(pGlu)apelin-13 amide significantly reduced LDL cholesterol (p<0.01; Fig. 4E) compared to 
DIO mice controls. In contrast, exendin-4(1-39) significantly increased LDL-cholesterol 
compared to the normal lean mice (p<0.01; Fig. 4E).   
Circulating amylase concentrations were comparable in all groups, demonstrating no adverse 
effect of treatment on the integrity of exocrine pancreas (Fig. 5A). Terminal plasma samples 
from all peptide treated groups showed significantly increased (p<0.01) circulating total 
GLP-1 concentrations (Fig. 5B), compared to saline-treated DIO controls. Mice treated with 
(pGlu)apelin-13 amide had a significantly higher pancreatic insulin content (p<0.01; Fig. 5C) 
compared to healthy lean control mice. However, no significant differences in pancreatic 
insulin content were observed between treatment groups and saline-treated DIO mice.  
 
3.4 Effects of apelin-13 amide and (pGlu)apelin-13 amide on bone composition and fat 
mass  
 Mice treated with (pGlu)apelin-13 amide showed a reduced final body weight (Fig. 5D) and 
percentage body fat mass (p<0.05; Fig. 5E) compared to saline-treated DIO mice. Exendin-
4(1-39) and (pGlu)apelin-13 amide both significantly increased bone mineral content (BMC) 
compared with high-fat saline treated controls, as well as lean controls (p<0.05; Fig. 5F). No 
significant effect on bone mineral density (BMD) was observed (data not shown).  
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3.5 Assessing effects of apelin-13 amide and (pGlu)apelin-13 amide on energy 
expenditure by indirect calorimetry 
No significant changes in oxygen consumption (Suppl. Fig. 1A-B) or carbon dioxide 
production (Suppl. Fig. 1C-D) were observed in peptide treated versus saline-treated DIO 
groups.  In contrast, both (pGlu)apelin-13 amide and exendin-4(1-39) treated mice showed 
significantly increased average RER compared to DIO saline-treated controls (p<0.05 and 
p<0.01; Suppl. Fig. 2AB).  This effect was demonstrated in both the light and dark cycles 
(Suppl. Fig. 2C-D).  (pGlu)apelin-13 amide treatment was also associated with an increase in 
overall average energy expenditure compared to saline-treated DIO mice (p<0.05; Suppl. Fig. 
3B) evident mainly in the dark cycle (p<0.05; Suppl. Fig. 3D).  In addition, (pGlu)apelin-13 
amide treatment caused mice to rear more often (Z axis beams broken) (p<0.05; Suppl. Fig. 
4F). No differences in any other ambulatory behaviour were observed (Suppl. Fig. 4A-E).  
The mice administered (pGlu)apelin-13 amide, had a significantly reduced accumulated food 
and energy intake over 24 h compared to saline-treated DIO mice (p<0.05; Suppl. Fig. 5A 
and 5B).  There were no significant effects observed in the number of feeding bouts of 
peptide-treated groups compared to saline-treated DIO mice (p>0.05; Suppl. Fig. 5C).  
 
3.6 Pharmacokinetic profile using radiolabelled pGlu(Tyr)apelin-13 amide 
Following an i.p. injection of radiolabelled pGlu(Tyr-I125)apelin-13 amide an initial 
radioactivity peak was reached in mouse plasma after 60 min (8.5 pM) but this rose to a new 
peak after 180 min (12.1 pM). The amount of radioactivity declined sharply thereafter 
reaching a level close to basal by 480 min (0.9 pM) and was completely gone by 24 h (1440 
min), indicating a half-life of approximately 1 h.  
 
4. DISCUSSION 
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Defective insulin secretion and impaired insulin action are major factors contributing to 
metabolic disarray and raised blood glucose concentrations in type 2 diabetes. 8,9  Lack of 
suppression of glucagon together with dysfunctional participation of the incretin hormones 
GLP-1 and GIP further compounds the problem. 28,29  The challenge for successful treatment 
of diabetes is to address these and other basic mechanisms that are defective in the disease 
state.  
Recent studies in our laboratory suggest that the adipokine apelin may have such therapeutic 
potential despite being rapidly cleaved and rendered inactive by ACE enzymes. 16 We have 
found that modification of native apelin-13 by the addition of an N-terminal pyroglutamate 
motif and/or an amide group at C-terminus conferred enzyme resistance and prolonged 
plasma half-lives. 16  Compared with the parent apelin-13 peptide, such modifications also 
significantly augmented effects on insulin release, adipocyte glucose uptake, and in vivo 
acutely induced satiety and evoked protracted glucose lowering in both lean and DIO mice. 
In the present study, long-term metabolic effects of two of these stable analogues, apelin-13 
amide and (pGlu)apelin-13 amide, were compared to the established antidiabetic agent 
exendin-4(1-39) using DIO mice that exhibited obesity, insulin resistance, and diabetes.  
Twice daily administration of (pGlu)apelin-13 amide or exendin-4 produced distinct 
reductions in non-fasting glucose, accompanied by hyperinsulinaemia, elevated circulating 
GLP-1, increased pancreatic insulin stores and enhanced glucose-induced insulin secretion. 
Such effects are well established for GLP-1 mimetics 30,31 and accord also with our previous 
data showing positive actions of apelin-13 on insulin secretion, cellular glucose uptake and as 
modulator of incretins. 16 Administration of apelin-13 amide also induced a range of 
beneficial actions in DIO mice but the effects were generally inferior to those observed with 
additional N-terminal pyroglutamate modification, which seemed to confer greater stability 
and bioactivity in vitro. 
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Consistent with marked therapeutic potential, DIO mice treated with both apelin-13 
analogues showed significant enhancement of intraperitoneal and oral glucose tolerance, 
which was associated with elevated plasma insulin concentrations. Such effects are likely to 
reflect direct beneficial actions of the peptides on pancreatic beta cells combined with 
possible effects also mediated via increased cellular glucose uptake and activity of the 
enteroinsular axis.  In support of this view, treatment with of (pGlu)apelin-13 amide, apelin-
13 amide or exendin-4 increased the insulin response and lowered the glycaemic excursion 
following feeding. Benefits in terms of insulin sensitivity, possibly mediated by actions of 
GLP-1 on glucose uptake in adipocytes and skeletal muscle, 32,33 might also contribute to 
glucose lowering, but insulin action, as measured by glucose lowering following acute insulin 
injection, was only enhanced in DIO mice treated with (pGlu)apelin-13 amide. HbA1C levels 
were only improved significantly at the end of the study in this same group, indicative of 
superior antidiabetic activity compared with both apelin-13 amide or exendin-4.   
As expected, prolonged high-fat consumption induced weight gain, deposition of adipose 
reserves and elevated circulating triglycerides.21,34 Treatment with either apelin-13 
analogue or exendin-4, significantly reduced body weight and circulating triglyceride 
concentrations with (pGlu)apelin-13 amide having an additional positive effect of reducing 
LDL-C and restoring body fat content to proportions similar to healthy lean mice. This 
reduced adiposity could contribute to improved insulin sensitivity as shown previously but no 
changes in HDL cholesterol were observed. Others have demonstrated that GLP-1 and 
exendin-4(1-39) significantly decreased total cholesterol, 35 which is consistent with our 
results.  It is also notable in the present study that concentrations of circulating amylase were 
similar to lean controls, suggesting no adverse reaction indicative of pancreatitis as claimed 
previously with some GLP-1 analogues. 36 
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Interestingly, the decreased body weights observed in all treatment groups were only 
accompanied by measurable inhibition of food intake in (pGlu)apelin-13 amide treated mice. 
Such action itself could in part be due to high co-localisation of APJ receptor with 
proopiomelanocortin (POMC) in the hypothalamic arcuate nucleus (Arc) which secretes α-
melanocyte-stimulating hormone (α-MSH), a strong suppressor of appetite. 37 Exendin-4 is 
noted to induce weight loss in humans, albeit its effects are less obvious and reproducible in 
animal models as observed by ourselves and others. 38,39 Since accurate measurement of food 
intake is difficult to record in normally housed freely fed mice, we would not rule out small 
contribution of decreased energy intake to the weight loss in all groups of mice. Nevertheless, 
it would seem likely that increase energy expenditure makes an important contribution to the 
declining weight, especially in the (pGlu)apelin-13 amide treated group. 
Both O2 consumption and CO2 production were increased in DIO mice, indicating enhanced 
whole body metabolism. 40 In support of key metabolic action, the decrease of fat mass 
observed in mice treated with (pGlu)apelin-13 amide was associated with increases in energy 
expenditure and spontaneous locomotor activity.  Interestingly, the average RER was higher 
in both the dark and light phase in (pGlu)apelin-13 amide treated mice. This is consistent 
with a switch from fat metabolism (RER=0.75) towards protein (RER=0.9) and/or 
carbohydrate (RER=1.0) metabolism, reflecting the depleted fat depots in treated mice. 
Increased body weight and fat mass impacts on bone deterioration. 41 It is notable that GLP-1 
has numerous effects apart from antidiabetic actions, including osteogenic properties. 39 
Administration of (pGlu)apelin-13 amide and exendin-4(1-39) exerted significant positive 
effects on bone mineral content (BMC).  The present findings in mice were consistent with 
those of rats fed a high-fat diet, as administration of GLP-1 and exendin-4(1-39) caused 
significant increases in BMC levels, 42 indicating extra-pancreatic effects of (pGlu)apelin-13 
amide. 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
In conclusion, these observations indicate that chronic treatment of DIO mice with apelin-13 
amide and in particular (pGlu)apelin-13 amide for 28 days exerted multiple beneficial effects 
similar to or better than treatment with the well-established GLP-1 therapeutic, exendin-4(1-
39). Other research indicates that apelin exerts important anti-inflammatory and 
cardioprotective effects, which could be helpful also in countering diabetes complications. 
These attributes make apelin-13 an attractive drug candidate and further studies are warranted 
to explore the antidiabetic effects of stable analogues and their potential for use in the 
treatment of the disease.   
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Figure Legends 
 
Figure 1. Chronic effect of twice daily administration of exendin-4(1-39), apelin-13 amide or 
(pGlu)apelin-13 amide (each at 25 nmol/kg bw) on (A) body weight, (B) % body weight 
change, (C) cumulative energy intake, (D) non fasting blood glucose and (E) plasma insulin 
during 28-day treatment. The black horizontal bar represents the treatment period. Values 
represent mean ± S.E.M. (n=8) where *p<0.05, **p<0.01 and ***P<0.001 is compared to 
high-fat fed saline treated mice, ∇∇p<0.01 and ∇∇∇p<0.001 is compared to lean mice fed on a 
normal diet. 
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dividing VCO2 by VO2. (B) Average RER (C), RER in the light, and (D) dark cycles are also 
included. Values represent the mean ± S.E.M. (n=6) where *p<0.05, **p<0.01 and 
***p<0.001 is compared to high fat fed saline treated mice. 
 
Supplementary Figure 3.  Effects of twice-daily i.p. administration of saline, exendin-4(1-
39), apelin-13 amide or (pGlu)apelin-13 amide (each at 25 nmol/kg bw) on (A) energy 
expenditure. Mice were placed in CLAMS metabolic chambers for 24 h (12 h dark period as 
shown by the black bar) and energy expenditure calculated using RER with the following 
equation: (3.815 + 1.232 x RER) x VO2.  (B) Average energy expenditure (C), energy 
expenditure in the light, and (D) and dark cycles are also included. Values represent the mean 
± S.E.M. (n=6) where *p<0.05 is compared to high fat fed saline treated mice. 
 
Supplementary Figure 4. Effects of twice daily i.p. administration of saline, exendin-4(1-
39), apelin-13-amide or (pGlu)apelin-13 amide (each at 25 nmol/kg bw) following 35-days 
administration on locomotor activity using optical beams. Mice were placed in CLAMS 
metabolic chambers for 24 h (12 h dark period as shown by the black bar). Activity counts in 
X-axis (lateral) (A-D) and Z-axis (vertical) (E-F) were recorded every min for the duration. 
Values represent the mean ± S.E.M. (n=6) where *p<0.05 is compared to high fat fed saline 
treated mice. 
 
Supplementary Figure 5. Effects of twice daily i.p. administration of saline, exendin-4(1-
39), apelin-13-amide or (pGlu)apelin-13 amide (each at 25 nmol/kg bw) following 35 days 
administration on food intake. Mice were placed in CLAMS metabolic chambers for 24 h and 
(A) food intake (B), energy intake, and (C) feeding bouts were measured for the duration. 
Values represent the mean ± S.E.M. (n=6) where *p<0.05 and **p<0.01 compared to high-fat 
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fed saline treated mice and ∇p<0.05, ∇∇p<0.01 and ∇∇∇p<0.001 is compared to lean mice fed 
on a normal diet 
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